自身免疫性肝炎治疗后应答不佳的影响因素分析

摘要/Abstract

摘要： 目的: 探讨自身免疫性肝炎(AIH)治疗后应答不佳的影响因素。方法: 回顾性分析常州市第三人民医院2012年1月至2019年10月收治的78例AIH患者的临床资料,依据治疗后应答情况分为应答良好组54例与应答不佳组24例。比较两组性别、年龄、临床症状(乏力、恶心、黄疸、纳差、腹痛)、血清抗核抗体(ANA)、抗线粒体抗体(AMA)、ALT、AST、总胆红素(TBil)、碱性磷酸酶(ALP)间的差异,多因素logistic回归分析AIH治疗后应答不佳的危险因素。结果: 应答不佳组患者存在乏力、恶心、黄疸患者,ANA、AMA抗体阳性患者占比分别为75.00%、79.16%、83.33%、79.17%、75.00%,显著高于应答良好组的25.00%、20.83%、16.67%、20.83%、25.00%(均P<0.05)。通过多因素Logistic回归分析证实,AIH患者存在乏力、恶心、黄疸症状,ALP高表达是治疗后应答不佳的危险因素,(均P<0.05)。结论: AIH应答不佳患者多存在乏力、恶心、黄疸症状,且血清ALP呈现出高表达,均为治疗后应答不佳的危险因素。

关键词: 自身免疫性肝炎, 应答不佳, 临床特征, 危险因素

Abstract: Objective To explore the factors influencing poor response on treatment of autoimmune hepatitis (AIH). Methods The clinical data of 78 patients with AIH admitted to our hospital from January 2012 to October 2019 were analyzed retrospectively. All patients were divided into good response group (n = 54) and poor response group (n = 24) according to the response after treatment.To compare the differences between the two groups in basic data (gender, age), clinical symptoms (whether there is fatigue, nausea, jaundice, poor appetite, abdominal pain), serum indexes (ANA, AMA, alt, AST, TBIL, ALP), we will find that there are different information lines and using multi factor logistic. C regression analysis to explore the risk factors of poor response after AIH treatment. Results Patients with fatigue, nausea and jaundice in the poor response group accounted for 75.00%, 79.16%, 83.33%, 79.17% and 75.00% of those with positive ANA and AMA antibodies, which were significantly higher than those in the good response group (25.00%, 20.83%, 16.67%, 20.83% and 25.00%, all P<0.05).The results of multivariate logistic regression analysis showed that patients with AIH had symptoms of asthenia, nausea and jaundice. The high expression of ALP was a risk factor for poor response after treatment, all of which were P<0.05. Conclusion Patients with poor response to AIH often have symptoms of asthenia, nausea and jaundice, and ALP in serum shows high expression, which are risk factors for poor response on treatment.

Key words: Autoimmune hepatitis, Poor response, Clinical characteristics, Risk factors

郭风彩, 吴剑明, 卫峥. 自身免疫性肝炎治疗后应答不佳的影响因素分析[J]. 肝脏, 2020, 25(7): 752-754.

GUO Feng-cai, WU Jian-ming, WEI Zheng. Analysis of influencing factors of poor response on treatment of autoimmune hepatitis[J]. Chinese Hepatolgy, 2020, 25(7): 752-754.

参考文献

[1] 杨炜炜. 自身免疫性肝炎患者血清腺苷脱氨酶水平与肝组织学的关系. 肝脏, 2018, 23:52-55.
[2] 赵萍萍, 邓志华. 自身免疫性肝炎的发病机制研究进展. 中华肝脏病杂志, 2017, 25:957-960.
[3] 张珺, 王绮夏, 马雄. 自身免疫性肝炎免疫学治疗进展. 临床肝胆病杂志, 2016, 32:1874-1877.
[4] 孟淼, 胡臻, 龚镭, 等. 自身抗体阴性的自身免疫性肝炎重叠原发性胆汁性胆管炎及原发性硬化性胆管炎1例报告. 临床肝胆病杂志, 2019, 35:1806-1808.
[5] 马雄, 邱德凯. 自身免疫性肝炎诊断和治疗共识(2015). 胃肠病学, 2016, 21:969-982.
[6] 邓拥军, 肖明中, 李晓东,等. 194例自身免疫性肝炎患者的临床特征分析. 临床肝胆病杂志, 2015, 31:1473-1476.
[7] 李燕妮, 周璐, 张洁, 等. 自身免疫性肝病首诊特征分析:单中心18年回顾性研究. 中华内科杂志, 2019, 58:366-371.
[8] 韩丹. 硫唑嘌呤联合泼尼松用于复发性自身免疫性肝病维持治疗的价值. 肝脏, 2019,24:559-561.
[9] None. Hepatitis: New predictor of response to treatment in autoimmune hepatitis type 1. Nature Reviews Gastroenterology & Hepatology, 2011, 9:5-5.
[10] 张洪文, 刘会敏, 林睿,等. 自身免疫性肝炎治疗应答不良患者的临床特点分析. 中华肝脏病杂志, 2017, 25:755-759.
[11] 郭丽萍, 周璐, 李树倩, 等. 熊去氧胆酸单药或联合免疫抑制剂治疗原发性胆汁性肝硬化-自身免疫性肝炎重叠综合征的疗效分析. 中华消化杂志, 2016, 36:155-160.
[12] 唐莹莹. 白介素-17、趋化因子10在儿童自身免疫性肝炎中的变化及意义. 实用临床医药杂志, 2019, 23:85-88.
[13] 张红梅, 张明, 郜志美. 自身免疫性肝炎患者外周血淋巴细胞亚群的变化. 实用肝脏病杂志, 2015, 18:76-77.
[14] 王炜, 孙伟, 苏建荣. 自身免疫性肝病患者的IgG4水平及相关血清学指标分析. 临床和实验医学杂志, 2018, 17:60-63.
[15] Verma S, Maheshwari A, Thuluvath P. Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes. Hepatology, 2010, 49:1396-1397.